Founded in 2011 as a spin-off of the University of Basel, Switzerland, PIQUR Therapeutics AG develops breakthrough targeted oncology and dermatology medicines for the treatment of cancer and genetic diseases. PIQUR’s lead compound bimiralisib focuses on the dual inhibition of the PI3K/mTOR pathway. Both PI3K and mTOR are clinically validated drug targets in oncology and dermato-oncology. PIQUR is a privately owned company that is backed by private investors and Versant Venture, a leading venture capital firm that specializes in investments in innovative biopharmaceuticals.